Possible interactions between dietary fibres and 5-aminosalicylic acid [corrected]
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Possible interactions between dietary fibres and 5-aminosalicylic acid [corrected]. / Henriksen, Camilla; Hansen, Steen Honoré; Nordgaard-Lassen, Inge; Andersen, Jens Rikardt; Madsen, Pia Lisbeth.
In: Therapeutic Advances in Gastroenterology, Vol. 3, No. 1, 01.2010, p. 5-9.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Possible interactions between dietary fibres and 5-aminosalicylic acid [corrected]
AU - Henriksen, Camilla
AU - Hansen, Steen Honoré
AU - Nordgaard-Lassen, Inge
AU - Andersen, Jens Rikardt
AU - Madsen, Pia Lisbeth
PY - 2010/1
Y1 - 2010/1
N2 - BACKGROUND: Potentially, a binding of 5-aminosalicylic acid (5-ASA) to dietary fibres could reduce the systemic absorption and increase the intraluminal amount [corrected]. The purposes of the study were to investigate if: (1) dietary fibres can bind 5-ASA in vitro, and (2) consumption of dietary fibres is related to disease activity in patients with ulcerative colitis (UC) treated with 5-ASA.METHODS: In vitro: 15 g of Ispaghula Husk, wheat bran, citrus-pectin, or wheat flour were incubated in a 37°C buffered solutions of 5-ASA (1 g/l) for 3 hours at pH 6 and 7. The concentrations of 5-ASA were determined before and after the incubation using HPLC. In vivo: patients with UC were interviewed two to three times during 6 months. The fibre consumption was estimated and related to the disease activity (CAI, CRP, Faecal-calprotectin) and quality of life (IBDQ).RESULTS: In vitro: 5-ASA was bound to Ispaghula Husk (5.3-10.0 mg/g) and wheat bran (4.6-5.5 mg/g), and to a minor degree to citrus-pectin. No differences were found in relation to pH. In vivo: 29 patients completed the scheduled interviews. No significant changes in fibre consumption were observed over time; however, patients consuming a diet high in fibre (>20 g/day) had significantly lower CRP (p <0.01) and faecal-calprotectin (p <0.01) than those consuming less fibre (<20 g/dg).CONCLUSIONS: Patients with a high intake of fibre had a lower disease activity than those with low intake. Ispaghula Husk bound 5-ASA in vitro, independent of pH. The effect might be clinically relevant in patients with UC treated with 5-ASA.
AB - BACKGROUND: Potentially, a binding of 5-aminosalicylic acid (5-ASA) to dietary fibres could reduce the systemic absorption and increase the intraluminal amount [corrected]. The purposes of the study were to investigate if: (1) dietary fibres can bind 5-ASA in vitro, and (2) consumption of dietary fibres is related to disease activity in patients with ulcerative colitis (UC) treated with 5-ASA.METHODS: In vitro: 15 g of Ispaghula Husk, wheat bran, citrus-pectin, or wheat flour were incubated in a 37°C buffered solutions of 5-ASA (1 g/l) for 3 hours at pH 6 and 7. The concentrations of 5-ASA were determined before and after the incubation using HPLC. In vivo: patients with UC were interviewed two to three times during 6 months. The fibre consumption was estimated and related to the disease activity (CAI, CRP, Faecal-calprotectin) and quality of life (IBDQ).RESULTS: In vitro: 5-ASA was bound to Ispaghula Husk (5.3-10.0 mg/g) and wheat bran (4.6-5.5 mg/g), and to a minor degree to citrus-pectin. No differences were found in relation to pH. In vivo: 29 patients completed the scheduled interviews. No significant changes in fibre consumption were observed over time; however, patients consuming a diet high in fibre (>20 g/day) had significantly lower CRP (p <0.01) and faecal-calprotectin (p <0.01) than those consuming less fibre (<20 g/dg).CONCLUSIONS: Patients with a high intake of fibre had a lower disease activity than those with low intake. Ispaghula Husk bound 5-ASA in vitro, independent of pH. The effect might be clinically relevant in patients with UC treated with 5-ASA.
U2 - 10.1177/1756283X09347810
DO - 10.1177/1756283X09347810
M3 - Journal article
C2 - 21180585
VL - 3
SP - 5
EP - 9
JO - Therapeutic Advances in Gastroenterology
JF - Therapeutic Advances in Gastroenterology
SN - 1756-283X
IS - 1
ER -
ID: 161726042